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ABSTRACT 
THE SYNTHESIS OF ALPHA 5 SUBTYPE SELECTIVE GABA(A) 
/BENZODIAZEPINE RECEPTORS LIGANDS 
 
by 
  
Poonam Biawat 
 
The University of Wisconsin-Milwaukee, 2014 
Under the Supervision of Professor James M. Cook 
 
GABAA complexes are a class of receptors that respond to the neurotransmitter GABA, 
the chief inhibitory neurotransmitter in the vertebrate CNS. A widely accepted 
pharmacological target for enhancing cognition is the benzodiazepine-binding site on the 
gamma-aminobutyric acid type A (GABAA) receptor complex. Inverse agonists acting at 
α5 subunits containing GABAA receptors are thought to act as cognitive enhancers while 
eliminating unwanted side effects associated with non-selective compounds. From the 
recent work of Rowlett, Cook et al. it was demonstrated that the novel α5 selective inverse 
agonist PWZ-029 (20) was active as a cognitive enhancer in rhesus monkeys in the 
CANTAB paradigm. This ligand (PWZ-029) is about 60-fold more selective for the α5 
subunit compared to α1, α2 and α3 GABA(A)ergic receptors. It is found that PWZ-029 
significantly attenuated scopolamine-induced impairment of contextual memory in rodents 
and primates. In the object retrevial task, PWZ- 029 showed only a modest trend for 
enhancement of performance, but when task difficulty was increased by testing with 
difficult trials only, PWZ-029 robustly increased performance. In addition, PWZ-029 
enhanced performance in the DNMS (Delayed non-matching to sample) task using the 10 
minute delay with distracters. This ligand also exhibited anxiolytic activity in some 
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primates and was an orally active anticonvulsant in rats (James Stables, NINDS). 
GABAA receptor complexes that contain subunits are abundantly expressed in the 
hippocampus and therefore considered to be a therapeutic target for treating cognitive 
disorders, like Alzheimer’s and ADHD. In order to search for better agents, a number of 
analogs of PWZ-029 were prepared in this research and have been sent out for biological 
testing. In order to do this a key benzylic bromide was prepared and purified which is a 
key to future work, stability issues with this bromide were solved which is important to 
success in this research. 
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           1. Introduction  
1.1. Molecular composition of GABA/benzodiazepine receptors  
The GABAA/benzodiazepine receptors are ligand-gated chloride channels which comprise 
the major inhibitory neurotransmitter in the central nervous system.1 The receptors are 
heteroligomeric membrane–bound protein complexes which play a central role in the 
molecular mechanisms in the CNS and are composed of several subunits and termed type 
A, type B, type C. In the case of type A receptors, the inhibitory effects of GABA mediated 
by these receptors can be modulated by a number of pharmacological agents that 
selectively bind to allosteric sites on these ion channels.2-5 GABAA receptors are 
heteropentameric assemblies of proteins derived from a family of subunits 
(6α3β3γ1δ1π1θ1ε and 3ρ)9,13 which form the chloride ion channel (Figure 1). The most 
common form of native GABAA receptors in the CNS are benzodiazepine sensitive and 
contain α, β, and γ subunits in a 2:2:1 stoichiometry.5,9,7 They are required to construct a 
fully functional recombinant GABAA/BzR chloride channel which closely mimic the 
biological, electrophysiological and pharmacological properties of native GABAA 
receptors.5,7,9 The benzodiazepine binding site is located at the interface between the α and 
γ subunits.10 While it is clear the γ subunit is  required for benzodiazepine binding,5,7 the 
fact that most native GABAA receptors contain an α subunit is in agreement with the α 
subunit as the key determinant of benzodiazepine binding and efficacy.5,7 However, it is 
clear the gamma subunit is also required for benzodiazepine binding.5,7  
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Figure 1. GABAA/ BzR/ Chloride Channel Complex 
Studies in molecular biology have identified 21 subunits which comprise a series of 
GABAA/BzR subtypes (ion channels); the principle ones of interest here are α1β3γ2 (α1 = 
ω1 = Bz1)3, α2β3γ2 (α2 = ω2 = Bz2), α3β3γ2, α4β3γ2, α5β3γ2 and α6β3γ213-16. Subtype 
assemblies which contain an α1 subunit (α1β3γ2) are present in most areas of the brain and 
are thought to account for 40-50% of GABAA receptors in the rat CNS. Subtype assemblies 
which contain α2 and α3 subunits, respectively, are thought to account for about 25% and 
17% of the GABAA/BzR receptors in the rat, respectively. The GABAA/BzR receptors 
which contain the α5 subunit are of minor abundance (5%) in the whole brain, but are 
significantly expressed in the hippocampus (Figure 2), where they comprise 15-20% of the 
diazepam-sensitive GABAA receptor population
3,7  and are predominantly co-assembled 
with β3 and γ2 subunits.7,15  The assembly of α1-6β3γ2 receptors in the rat are very similar 
to those in the human CNS. 
3 
 
 
 
 
Figure 2: Distribution of α5 receptors in the hippocampus. Reprinted with permission of 
the author.  
The majority of Bz1 GABAA receptors are composed of 2α, 2β and 1γ subunits. Each 
subunit has per convention a “plus” and a “minus” side (Figure 3).18,19 Consequently, the 
subunit interfaces consist of the plus and minus sides of neighboring subunits. The 
modulatory benzodiazepine binding site is located at the α+γ- subunit interface and is larger 
than, but homologous to the two agonist (GABA) binding sites, which are located at the 
β+α- subunit interfaces. The absolute subunit configuration for the α1β2γ2 GABAA receptor 
appears to be γβαβα when viewed counterclockwise from the synaptic cleft.17  
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Figure 3. Absolute subunit arrangement of the α12βγ2 GABAA receptors when viewed 
from the synaptic cleft.18,19 
1.2. History 
Although the BZs were first introduced into clinical practice in the early 1960s, it was not 
until 1975 that these drugs were shown to act by potentiating the inhibitory actions of 
GABA in the brain.1,20 The presence of high affinity, specific binding sites for BZs in the 
mammalian brain was then demonstrated by Squires, Haefely et al. 3,21,22 Converging lines 
of evidence established that these sites were contained in the same macromolecule as the 
GABA sites and the chloride channel, moreover that all three elements were coupled 
allosterically.23-25 The term “GABA/BZ receptor” came into use for this complex (and is 
still encountered). Until recently, progress in this field was driven by the synthesis of a vast 
range of BZs and BZ-like drugs, which acted at the allosteric BZ sites of brain GABAA 
receptors and exhibited clinical anxiolytic or sedative properties which correlated to their 
binding-potencies in the CNS.26 The structure of some ligands which act at the BZ site are 
shown in Figure 4. 
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Figure 4. GABA, diazepam, triazolam and midazolam. 
1.3. Pharmacology 
Overall, the design, synthesis and biological evaluation of αxβ3γ2 (x1-6) subtype selective 
ligands will provide the pharmacological tools necessary to determine which GABAA/BzR 
subtype mediates with physiological response. This will also provide entry into potential 
therapeutic agents to treat anxiety disorders, sleep disorders, epilepsy as well as enhance 
cognition in age-associated memory impairment in the absence of deleterious side effects. 
Ligands that bind to the BZ site can influence the binding of GABA to its receptor and 
thereby alter the flux of chloride ions through the ion channel.28  Ligands at the BZ site are 
categorized as agonist (positive allosteric modulator), inverse agonist (negative allosteric 
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modulator), or antagonist, all of which can bind with high affinity. Agonists enhance the 
effects of GABA by increasing the frequency of channel opening to provide a net 
hyperpolarization of the neuron and a decreased excitability. BZ inverse agonists have the 
opposite effect and decrease the flow of chloride ions (negative modulators, NAM) which 
results in a depolarization and an increased neuronal excitability. Between the two efficacy 
extremes, there is a continuum of partial agonists and partial inverse agonists as well as 
antagonists, the latter of which do not alter chloride flow and are functionally silent. These 
different efficacies are reflected in different behavioral effects of BzR site ligands in 
mammalian species.  
The benzodiazepine binding site is the most explored of the GABAA receptor modulatory 
sites and this central role carries with it a direct influence on many diseases of the central 
nervous system.29-31 The interaction with benzodiazepines has been a major influence in 
studies on GABA receptors because of the long history of the therapeutic application of 
benzodiazepines as anxiolytics, anticonvulsants, sedative-hypnotics, and muscle 
relaxants.5,32 It has been found that certain disease states, as well as tolerance and 
dependence are related to the up regulation or down regulation of specific subunits.33 The 
sedative properties of diazepam appear to be due to the interaction at the α1 subtype, 
whereas the anxiolytic effects originate from α2 and/ or α3 subtypes (Table 1). In contrast, 
it has been reported that α1 subtypes play a significant role in the sedative-hypnotic, ataxic, 
amnestic and addictive effects of benzodiazepines. 
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      Table 1. Action of Benzodiazepine at GABAA α (1-6)β3γ2 Receptor Subtypes.33 
Subtype Associated Effect 
α1 Sedation, anterograde amnesia, some anticonvulsant action, ataxia and  
addiction 
α2 Major anxiolytic, hypnotic (EEG) at higher doses maybe some muscle 
relaxation at high doses, some anticonvulsant action 
α3 Some anxiolytic action, maybe some muscle relaxation at high doses  
α4 Diazepam-insensitive site 
α5 Cognition, temporal and spatial memory  
α6 Diazepam-insensitive site 
 
Modified in 2007 by Clayton, Cook et al. from a talk by Ruth McKerman at the ACNP meeting in 
Dec 2004.17 
 
The hippocampus is relatively enriched in α5 containing GABAA receptors compared to 
other brain areas.34 Interest in BzR/GABAA α5 subtypes has been stimulated by the report 
of Mohler et al.35 on α5 “knock in” mice. This group has provided strong evidence that 
hippocampal extrasynaptic α5 GABAA receptors play a critical role in associative learning 
and memory.35 In addition, an α5 subtype selective inverse agonist was shown by Bailey, 
Helmstetter, Cook et al.36 to be important in acquisition of fear conditioning and provided 
further evidence for the involvement of hippocampal GABAA/benzodiazepine receptors in 
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learning and anxiety.36 A selective α5 inverse agonist might have therapeutic utility as an 
agent to enhance cognition without the unwanted side effects associated with activity at 
other receptor subtypes.36,37 Most drugs currently used in the treatment of cognitive 
deficiency act through the cholingric system and have moderate clinical efficacy. GABAA 
α5 subtype selective inverse agonists may offer an alternative mechanism for the 
symptomatic treatment of memory impairment associated with Alzheimer’s disease and 
related dementias.4,8,34  This is, in part, because cholingeric neurons are destroyed rapidly 
in Alzheimers, while GABA(A) receptors remain functional throughout the disease or at 
least until the very end (McKernan et al.).  
1.4. Molecular modeling 
A simple unified pharmacophore receptor model for the agonist, antagonist and inverse 
agonists at the benzodiazepine binding site of GABAA receptors has been developed in 
Milwaukee39-44 and is shown in Figure 5 using the techniques of chemical synthesis, 
radioligand binding and receptor mapping based on the synthesis of rigid ligands.41 The 
experimental data of recent and past years have been evaluated, and definite trends with 
regards to the orientation of the regions of the protein relative to the descriptors of the 
pharmacophore receptor model have been identified and are employed in this work by 
using this ligand-based pharmacophore receptor model and our α1β2γ2 GABAA receptor 
model.45,46 The important points of the model include three anchor points which were 
termed L1, H1, and H2; region L1 represents a center of lipophilic interaction with the 
ligands, while H1, H2 and A2 represent two hydrogen bond donor sites and one hydrogen 
bond acceptor site on the receptor protein, respectively, in the receptor binding domain.47 
Three additional lipophilic regions were also proposed, termed L2, L3 and LDi, which are 
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important for binding affinity and selectivity as well as efficacy of the ligands. It is 
noteworthy to mention that lipophilic interactions between a ligand and the receptor 
include Vander Waals interactions, as well as potential π-π and p-π stacking between the 
aromatic moieties of the ligand and groups on the receptor protein.    
 
  
Figure 5. Diazepam in the Pharmacophore/Receptor Model for the BzR Site. 
Pyrazolo[3,4-c]quinolin-3-one CGS-9896 (dotted line), a diazadiindole (thin line), and 
diazepam (thick line) fitted to the inclusive pharmacophore model for the BzR. Sites H1 
and H2 represent hydrogen bond donor sites on the receptor protein complex, while A2 
represents a hydrogen bond acceptor site necessary for potent inverse activity in vivo. L1, 
L2, L3 and LDi are four lipophilic regions in the binding pharmacophore. Descriptors S1, 
S2, and S3 are regions of negative steric repulsion.  
 Areas of negative steric repulsion with the protein are described as S1, S2, and S3. 
Examination of the included volumes indicated that the shapes of binding pockets for α1, 
α2 and α3 subtypes are very similar to each other. Region L2 for the α5 containing subtype 
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appeared to be larger in size than the analogous region of the other receptor subtypes. The 
LDi region in contrast appeared to be larger in the α1 subtype than in the other subtypes.49 
The receptor subtype descriptor termed the DI site is related to α4 and α6 BzR, which is 
devoid of /or has a very small lipophilic pocket L3 in comparison to the other four (α1, α2, 
α3, and α5) subtypes. The DI region appears to be near the outside of the receptor binding 
cleft and may be important as well for interactions at the α1 subtype which results 
sometimes in increased α1 subtype selective affinity. With the aid of these models, several 
series of ligands have been synthesized and evaluated pharmacologically to determine the 
interaction with the GABA/benzodiazepine receptor subtype selective ligands as well as 
the physiologically related response.17 
2. Objective of the Research 
To employ PWZ-029 (19) as a template and prepare analogs related to this lead compound. 
The analogs must be similar in structure and electron density or the entire α5 subtype 
selectivity will change.17 The goal is to make analogs that have 40-50% negative efficacy 
(in oocytes) as compared to 20% exhibited by PWZ-029, while maintaining little or no 
efficacy at α1, α2 and α3 subtypes. 
 
3. Results and Discussion 
3.1 Synthesis of 8-Substituted Imidazobenzodiazepines 
As mentioned above, the α5 subtypes are primarily found in the hippocampus34 which is 
an important brain region for memory and learning.36 Studies carried out by Mohler et al.35 
on α5 knockin mice, as pointed out previously, provided strong evidence that hippocampal 
extrasynaptic α5 GABAA receptors play a critical role in associative learning.35 The 8-
11 
 
 
 
substituted imidazobenzodiazepines such as RY-23 and RY-24 exhibited a greater affinity 
and selectivity at the α5 subtype than ligands previously reported.36 Previously, the subtype 
selective inverse agonist activity49-53,54 of a series of α5 subtype selective ligands [(6, RY-
023), (7, RY-024), (8, RY-079) and (9, RY-080)] was reported. The design was based on 
the structure of 5 (Ro 15-4513) and, in addition, McKernan, Atack et al. (see 10) reported 
several related ligands as well.55,56 These ligands are BzR inverse agonists in vivo and have 
been shown to enhance cognition.13-16 One of these ligands was shown by Bailey et al. 36 
to be important in the acquisition of fear conditioning and provided further evidence for 
the involvement of hippocampal GABAA/benzodiazepine receptors in learning and 
anxiety. This was supported by the work of DeLorey et al.57 in a memory model with a 
ligand closely related to α5 subtype selective inverse agonists 6 and 7. 
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Figure 6. Ro 15-4513 (5), RY-023 (6), RY-024 (7), RY-079 (8), RY-80 (9) and the 
Merck compound (10). 
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The ligands 6-9 and 10 depicted in Figure 6 were 40-70 fold more selective for α5 subtypes 
in comparision to α1 subtypes; however, better subtype selectivity remains a goal of 
paramount importance today. In collaboration with Sieghart et al. the efficacy of inverse 
agonist RY 24 (7) was determined. It was demonstrated that RY 24 (7) was a potent inverse 
agonist at α5 subtypes in oocytes with a much weaker efficacy at the other subtypes.  
 
Figure 7. Subtype selective efficacy of RY-24 (7); dose response curves for RY-24 in oocytes 
expressing different subunit combinations of GABAA receptors. Subtype combinations are 
indicated in legends. cRNA–injected Xenopus oocytes were held at – 60 mV under two-electrode 
voltage clamp. Increasing concentrations of RY-24 were superfused together with a GABA 
concentration eliciting ~ 20% of the maximal current amplitude. RY-24 was pre-applied for 30 sec 
before the addition of GABA, which was co-applied with the drugs until a peak response was 
observed. Data were normalized for each curve assuming 100% for the response in the absence of 
RY-24. RY-24 was made up and diluted as a stock solution in DMSO. Final DMSO concentrations 
perfusing the oocyte were 0.1%. Values are presented as mean ± SD of at least 4 oocytes from at 
least 2 batches.  
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The lipophilic substituent at R8 of RY-24 7 and RY-80 9 decreased the affinity for α1, α2 
and α3 subtypes; it retained affinity for α5 subtypes. This data again supports the 
importance of the occupation of the lipophilic pocket L2 for potent selectivity at the α5 
subtype.  
Table 2. In Vitro Receptor Binding Data of α5 Ligands. Binding Affinity at αxβ3γ2 
GABAA/BzR Receptor Subtypes (Values Reported in nM ) 
 
 "Synthesis and Pharmacological Properties of Novel 8-Substituted Imidazobenzo-diazepines: 
High Affinity, Selective Probes for α5 Containing GABAA Receptors,"Liu, R.; Hu, R.; Zhang, P.; 
Skolnick, P.; Cook, J. M., J. Med. Chem., 39, 1928-1934 (1996).  
 
As previously stated, the hippocampus contains the greatest concentration of α5-containing 
receptors in the CNS34,58 and it is possible that these hippocampal α5 receptors may also 
regulate alcohol-motivated responding following systemic administration of an α5-
selective agent. Furthermore, RY-24 also antagonized the motor-impairing and sedative 
effects of ethanol in Long-Evans rats. Combined with additional studies within the ventral 
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pallidum (VP), it has been proposed that the GABAergic systems within the VP and 
hippocampal pathways may represent new extensions of the mesolimbic ethanol reward 
circuitry. Although these data do not strongly support a direct role for the modulatory 
influences of intrinsic efficacy in the behaviors examined, the synthesis of α5 subtype 
selective ligands provides researchers a unique opportunity to explore the role of this 
subtype in the neurobehavioral effects of alcohol.50,59 However, the partial efficacy (inverse 
agonist, negative modulation) of RY-23 and RY-24 at α1 and α2 subtypes precludes 
potential clinical uses of such agents for both agents are proconvulsant and RY-24 is also 
convulsant.  
Additional behavioral studies on RY-24 were performed by Helmstetter et al. and provided 
further support for the role of the hippocampus in anxiety and learning.36 Moreover, the 
data suggested that Bz BSs within the hippocampus are important for the acquisition of 
fear conditioning. Although this subtype selective ligand has been shown to be an inverse 
agonist at the α5 subtype,51,60 this study suggested that RY-24 may act as an agonist at 
other alpha subtypes because larger doses of RY-24 were not as anxiogenic as the smaller 
doses and resulted in decreased learning. Consistent with the studies of Stephens et al. 
using α5 knock-out mice61 and the efficacy studies of Lüddens, June and Cook et al.,62 
these findings support the concept that the pharmacology observed depends upon the dose, 
behavioral paradigm employed and subunit composition activated. Ligands such as RY-24 
have proven to be valuable in the study of the biochemical and pharmacological properties 
of GABAA receptors and have permitted insight into the role this protein plays in anxiety 
and learning. In order to repeat and further investigate the physiological processes mediated 
by RY-24 at α5 subtypes, a large scale synthesis was executed. In brief, isatoic anhydride 
15 
 
 
 
11 and sarcosine were heated in DMSO to form the benzodiazepine 12 in 84% yield. 
Benzodiazepine 12 was treated with bromine in the presence of CH3COOH and H2SO4 to 
provide the bromide 13 in 80% yield, as illustrated in Scheme 1. Deprotonation of 13 with 
KOtBu in THF followed by treatment with diethyl chlorophosphate at -30 °C provided the 
intermediate enol phosphate.63 The enol phosphate was stirred with a solution of t-butyl 
isocyanoacetate and KOtBu at -30 °C to yield the imidazobenzodiazepine 14 in 70% yield. 
This bromide was converted into 6 by a Heck-type coupling reaction 49,51 using bis(acetate) 
bis(triphenylphosphine) palladium(II) to provide TMS analog RY 23 (6) and the silyl 
group was removed in high yield on treatment with TBAF/THF to provide gram quantities 
of RY 24 (7).49  
Scheme 1: Large Scale Synthesis of RY-23(6) and RY-24(7) 
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4. Synthesis of α5 subtype selective inverse agonist PWZ-029 on multigram 
scale  
PWZ-029 (19) was effective in improving memory and cognition, especially in models 
with baseline cognitive deficits. The high specificity of PWZ-029 (19) for α5-containing 
GABAA receptors has successfully negated adverse side effects of seizures and sedation, 
which are commonly observed with typical negative modulators (BZ) and nonselective 
inverse agonists of the GABAA complex. The novel ligand PWZ-029, which was 
synthesized on large scale and characterized electrophysiologically, possesses in vitro 
binding selectivity and moderate inverse agonist functional selectivity at α5-containing 
GABAA receptors (20%). This ligand has also been examined in rats in the passive and 
active avoidance, spontaneous locomotor activity, elevated plus maze and grip strength 
tests, primarily predictive of the effects on memory acquisition, basal locomotor activity, 
anxiety level and muscle tone, respectively. The improvement of task learning was detected 
at the dose of 5 mg/kg in the passive (hippocampal-driven), but not the active avoidance 
test. The inverse agonist PWZ-029 had no effect on anxiety nor muscle tone, whereas at 
higher doses (10 and 20 mg/kg) it decreased locomotor activity in this one paradigm. This 
effect was antagonized by flumazenil and also by the lower (but not the higher) dose of an 
agonist (SH-053-2’F-R-CH3) selective for GABAA receptors containing the α5 subunit. 
The hypolocomotor effect of PWZ-029 was not antagonized by the antagonist ß-CCt 
exhibiting a preferential affinity for α1-subunit containing receptors. These data suggest 
that moderate negative modulation at GABAA receptors containing the α5 subunit is a 
sufficient condition for eliciting enhanced encoding/consolidation of declarative memory, 
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while the influence of higher doses of modulators at these receptors on motor activity 
shows an intricate pattern whose relevance and mechanism wait to be defined. 
The effect on motor activity is often times confounded by stereotypical behavior. In all 
other studies PWZ-029 in rodents and primates, no sedation was observed. One desirable 
property in this regard is the pro-amnesic activity of BZ site inverse agonists, repeatedly 
reported in animal models,64,65 as well as in human volunteers.66,67 However, this desirable 
effect is confounded by different concomitant psychomotor effects (increased vigilance, 
anxiogenic and/or proconvulsant state), some of which have been described in memory 
studies with non-selective inverse agonists in humans, urging their early termination.66 
Point mutated mice could not be used to identify the receptor subtypes mediating the 
promnesic activity of inverse agonists because an unexplained switch to the agonist mode 
of action occurs when an inverse agonist at wild type diazepam-sensitive recombinant 
GABAA receptors is altered in the respective point-mutated receptors.
68,69 Thus, inverse 
agonists exerted agonistic-like sedative and anticonvulsant effects in mice with the point-
mutated α1 subunits,69 while the corresponding experiments in models of learning and 
memory were not performed.69 Nevertheless, behavioral examination of genetically 
modified animals conducted, to date, has indicated the α1 and α5 subunit-containing 
GABAA receptors comprise the ‘memory-modulating’ population of these receptors.70,71 It 
is notable, as mentioned, that GABAA receptors containing the α5 subunit are abundantly 
expressed in the hippocampus,7,72,73 the structure substantially involved in memory 
formation.74 Recent evidence from animal studies with affinity-selective75 or efficacy-
selective ligands76-78 has confirmed that the α5 subunit was significantly involved in 
cognition enhancement mediated by the negative modulation of GABAA receptor 
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functions. Moreover, it was shown in humans that pre-treatment with an α5 efficacy-
selective inverse agonist significantly reduces the amnesic effect of alcohol on learning a 
word list.79 However, the affinity- or efficacy-selectivity of the ligands, as well as the 
diversity of the behavioral tasks used in their characterization to date, were of limited 
extent, which necessitated screening of newer BZ site negative modulatory ligands, to 
determine the putative therapeutic role of such compounds in various disorders with 
diminished cognitive capabilities in humans.80 
 In this regard, the BZ site ligand PWZ-029 was synthesized (Scheme 2) and prepared on 
large scale. A mixture of 5-chloroisatoic anhydride 15 and sarcosine in DMSO was heated 
to reflux to furnish benzodiazepine 16 in 84% yield. Potassium t-butoxide was added to a 
solution of 16 in THF at 0 °C and stirred for 20 min. The reaction was cooled to -35°C and 
diethylchlorophosphate was added slowly. After stirring at 0 °C for 30 minutes, the reaction 
mixture was cooled to -78 °C and ethyl isocyanoacetate was added followed by potassium 
t-butoxide to form 17 in 89% yield. A solution of imidazobenzodiazepine 17 can be 
reduced with LiBH4 to furnish alcohol 18 in 67% yield as colorless crystals. To a slurry of 
KOH in DMSO at room temperature were added alcohol 18 and CH3I to give PWZ-029 
(19), as an off-white powder in 95% yield on 1-15 gram scale.  
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Scheme 2: SYNTHESIS OF PWZ-029 
 
Electrophysiology experiments in Xenopus oocytes demonstrated that PWZ-029, at a 
concentration of 100 nM, significantly reduced GABA initiated control currents, thereby 
indicating a partial inverse agonist effect of PWZ-029 on GABA(A) receptors possessing 
the α5 isoform (Figure 8). Illustrated in Figure 8, are the concentration–effect curves for 
modulation of GABAA elicited currents by PWZ-029 on Xenopus oocytes expressing 
GABAA receptor subtypes α1β3γ2, α2β3γ2, α3β3γ2, and α5β3γ2, concentrations of 
GABAA that elicit 3% of the maximum GABAA-triggered current of the respective cells 
were applied alone (EC3) and with various concentrations of PWZ-029. Control currents 
represent responses in the absence of PWZ-029. Data points represent means±SEM from 
4 oocytes from ≥2 batches [1μM PWZ-029 resulted in 114±4%, 105±8%, 118±5% and 
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80±4% of control current (at GABAA EC3) in α1β3γ2, α2β3γ2, α3β3γ2, and α5β3γ2 
receptors, respectively]. All these values except the one for α2β3γ2 receptors were 
significantly different from that of the respective control currents (p<0.01, Student's t-test). 
Note that 100 nM is the pharmacologically relevant concentration.  
            Table 3. In Vitro Binding Affinities of PWZ-029 at GABAA/BzR subtypes 
Code  MW  α1  α2  α3  α4  α5  α6  
Merck  291.73  >300  >300  >300  ND  38.8  >300  
Moltech  291.73  920  ND  ND  ND  30  ND  
UNC-
Roth  
291.73  362.4  180.330  328.2  ND  6.2  ND 
 
 
                                  Figure 8. Oocyte data for PWZ-029 by Sieghart et al.82 
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This ligand as mentioned, has also been examined in rats in the passive and active 
avoidance, spontaneous locomotor activity, elevated plus maze and grip strength tests, 
primarily predictive of the effects on the memory acquisition, basal locomotor activity, 
anxiety level and muscle tone, respectively. The improvement of task learning was detected 
at the dose of 5 mg/kg in the passive avoidance task (Figure 9).  The passive avoidance 
task is a one trial fear-motivated avoidance task in which the mouse learns to refrain from 
stepping through a door to an apparently safer but previously punished dark compartment. 
The latency to refrain from crossing into the punished compartment serves as an index of 
the ability to avoid, and allows memory to be assessed.  
 
Figure 9. Fear conditioned contextual memory of PWZ-029 
The PWZ-029 at 5 mg/kg, administered before the acquisition session, significantly 
increased retention session latency relative to the control group.82 The inverse agonist 
PWZ-029 (47) had no effect on anxiety or muscle tone, whereas at higher doses (10 and 
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20 mg/kg) it decreased locomotor activity. This effect was antagonized by flumazenil and 
also by the lower (but not the higher) dose of an agonist (SH-053-R-CH3-2′F) selective for 
GABAA receptors containing the α5 subunit. The hypolocomotor effect of PWZ- 029 (47) 
was not antagonized by the antagonist BCCt, which exhibits a preferential affinity for α1- 
subunit-containing receptors. These data suggest that moderate negative modulation at 
GABAA receptors containing the α5 subunit is a sufficient condition for eliciting enhanced 
encoding/consolidation of declarative memory, while the influence of higher doses of 
modulators at these receptors on motor activity shows an intricate pattern whose relevance 
and mechanism await to be defined.82 In fact, in the conflict paradigm in Rowlett’s lab in 
rhesus monkeys, PWZ-029 (19) was a weak anxiolytic with no sedation observed in either 
the suppressed or nonsuppressed portion of the test.  Recently, Stables et al. at NINDS has 
shown PWZ029 to be a weak anticonvulsant. Therefore PWZ-029 (47) an α5 inverse 
agonist cannot be proconvulsant or convulsant, and, consequently, will not exhibit the side 
effects of other inverse agonists (NAM). 
 
 
Figure 10. Passive avoidance task82  
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The effects of DMCM (0.2 mg/kg) and PWZ-029 (2, 5 and 10 mg/kg) on retention performance in 
a passive avoidance task (*p<0.05 compared to solvent (SOL) group). Number of animals per 
treatment group: 10.  
CANTAB Approach (Rowlett, and Cook et al.)83 
Recent studies by Rowlett, and Cook et al. on PWZ-029 showed that this ligand acted as 
an inverse agonist at α5/GABAA receptor subtypes which enhanced memory. Rowlett has 
used several primate models, including the Cambridge Neuropsychological Test 
Automated Battery, or CANTAB.  A clear strength of the CANTAB approach is that its 
tasks are based on corresponding procedures developed for human patients, which greatly 
facilitate the ultimate goal of translating findings from monkeys to humans.   
Because PWZ-029 has been shown to be safe and to have cognitive-enhancing effects in 
rodents82, experiments were initiated with this compound in rhesus monkeys as mentioned.  
Initial results, shown in Figure (11), are quite provocative and exciting:  PWZ-029 
enhanced performance in the DNMS (Delayed non-matching to sample) task using the 10-
min delay with distracters (Figure 11A) and although it had no effect alone, PWZ-029 
completely reversed the scopolamine-induced deficit in the ORD (Object Retrieval with 
Detours) task (Figure 11B).  Interestingly, PWZ-029 induced anti-conflict (anxiolytic) 
effects in monkeys without the concomitant response rate suppressing effects characteristic 
of BZ-type drugs such as diazepam (Figure 11C).  It is felt that these latter effects are due 
to PWZ-029’s partial agonist effects at α2/3GABAA receptor subtypes, whereas the 
cognition-enhancing effects of this compound are due to inverse agonist (NAM) action at 
α5/GABAA receptors. The lack of negative efficacy in PWZ-029 at α1, α2 and α3 subtypes 
as compared to proconvulsant/convulsant RY-24 is responsible for the safe profile of PWZ-
029. 
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PWZ-029 (19) provides an important lead compound based not only on potential 
effectiveness against cognitive impairment, but also as a potential treatment for anxiety 
and agitation in older patients with dementias, similar to the anxiolytic effects of classical 
BZs (Meehan et al. 2002).  Studies will continue with PWZ-029 and expand them to 
include comparative studies with non-selective agonists and α5GABAA-preferring 
agonists; as well as with pre-treatments with α5GABAA-preferring antagonists such as 
XLi-093.  In addition, in our initial screens compounds will be sought with similar, and 
hopefully improved, efficacy profiles.  For example, a compound that is an α5GABAA 
partial inverse agonist, an α2/3GABAA-preferring partial agonist, but ineffective at 
α1GABAA receptors is both desirable and feasible in our synthesis/screening program.  
 
          
  
25 
 
 
 
Figure 11: Preliminary profile of cognitive enhancing and anxiolytic-like effects of PWZ-029 in 
monkeys. Data are from n=2 monkeys (A &C) and n=4 monkeys (B). Red arrow indicates the dose 
(0.01mg/kg, i.v.) of PWZ-029 tested in A & B  
Importantly, in the ORD task, PWZ-029 showed only a modest trend for enhancement of 
performance (Fig. 12A), but when task difficulty was increased by testing with difficult 
trials only, PWZ-029 robustly increased performance (Fig. 12B).  This enhancement was 
reversed by administration of the α5GABAA-preferring antagonist XLi-093, and this 
antagonism, in turn, was reversed by increasing the dose of PWZ-029 (Fig. 12C).  Finally, 
PWZ-029 completely reversed deficits in performance induced by the memory-impairing 
anti-cholinergic scopolamine (Fig. 12D). 
               
Figure 12. Cognitive-enhancing effects of PWZ-029 in the rhesus monkey Object 
Retrieval with Detours (ORD) task (N=5 monkeys).  A. Effects of PWZ-029 on ORD tests 
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consisting of both easy and difficult trials. No effect of the compound was observed (mean 
% correct first reaches, p>0.05, repeated measures ANOVA).  B. PWZ-029 enhanced 
performance in the ORD task when tested with difficult trials only (*p<0.05 vs. vehicle, 
V, Bonferroni t-tests).  C.  Enhancement of ORD performance by 0.018 mg/kg of PWZ-
029 was attenuated by the α5GABAA-preferring antagonist XLi-093, and this antagonism 
was surmountable by increasing the PWZ-029 dose (*p<0.05 vs. vehicle, **p<0.05 vs. 
0.018 mg/kg PWZ-029, Bonferroni t-tests).  D.  PWZ-029 reversed performance impaired 
by 0.01 mg/kg of scopolamine. (*p<0.05 vs. vehicle; **p<0.05 vs. scopolamine alone, 
Bonferroni t-tests).  
 
5. Synthesis of PWZ-029 analogs 
In order to obtain ligands with potentially a better efficacy profile (oocytes) than PWZ-
029, negative modulation of 40% to 50% as compared to 20% is a goal of these studies. 
The approach is in agreement with our PWZ-029 template and by a recent study on 
compounds (NAM) patented by Roche.84 Several new analogs have been proposed here 
and docked in the Milwaukee-based pharmacophore by Clayton et al. 85  
                 
                                    28                       Affinities for αxβ3γ2(x= 1-6) benzodiazepine receptors isoforms 
 Alpha 1 
 
Alpha 2 Alpha 3 Alpha 4 Alpha 5 Alpha 6 
  Roche     174.3  185.4 79.6 ND 4.6 ND 
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               Affinities for αxβ3γ2(x= 1-6) benzodiazepine receptors isoforms 
Code  MW  α1  α2  α3  α4  α5  α6  
Merck  291.73  >300  >300  >300  ND  38.8  >300  
Moltech  291.73  920  ND  ND  ND  30  ND  
UNC-Roth  291.73  362.4  180.330  328.2  ND  6.2  ND 
 
Figure 13: Receptor binding affinity data of PWZ-029 (19) determined by Merck, Moltech and 
Roth for Cook et al. and the Roche difluoro ligand 28 The new analogs of PWZ-029 are of strong 
interest due to the recent results on contextual memory impairment data wherein doses of 
scopolamine decreased memory while the α5 ligand reversed this, as described above. 
Synthesis of PB-I-052 
 
                           18 (1.5 gram)                                                                21 
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Synthesis of PB-I-054 
          
                       21 (1 gram)                                                                22 
Synthesis of PB-I-056 
       
                        21 (1 gram)                                                                     23 
 
Figure 14. Oocyte data of PB-I-056 
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            Synthesis of PB-I-059 
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Synthesis of PB-I-063 
      
                    21                                                                                 27 
               Synthesis of PB-I-076 
 
                      20                                                                                     28 
6. Conclusion 
From the recent work of Rowlett, it was demonstrated that novel α5 selective inverse 
agonist PWZ-029 (19) enhanced cognition in rhesus monkeys in the CANTAB paradigm. 
This ligand had the ability to reverse cholinergic deficits in performance induced by the 
antimuscarinic scopolamine under mixed trial conditions. In the ORD task, PWZ-029 
showed only a modest trend for enhancement of performance, but when task difficulty was 
increased by testing with difficult trials only, PWZ-029 robustly increased performance.  
This enhancement was reversed by administration of the α5 GABA (A) subtype selective 
antagonist XLi-093 and this antagonism in turn was reversed by increasing the dose of 
PWZ-029. In addition, PWZ-029 enhanced performance in the DNMS task using the 10 
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minute delay with distracters. This ligand also exhibited anxiolytic activity in some 
primates and was a weakly active anticonvulsant in rats (NINDS, Jim Stables et al). These 
findings are consistent with a role for PWZ-029 (21) at α5 GABAA receptors in the 
treatment of age associated memory impairment and Alzheimer’s disease. It is the subject 
of an SBIR I grant submitted December 5th, 2012 by Physiogenix which was funded by 
NIH 
          7. General Experimental Details   
All reactions were carried out under an argon atmosphere with dry solvents using 
anhydrous conditions unless otherwise stated. Tetrahydrofuran (THF) and diethyl ether 
were freshly distilled from Na/benzophenone ketyl prior to use. Dichloromethane was 
distilled from calcium hydride prior to use. Methanol was distilled over magnesium sulfate 
prior to use. Benzene and toluene were distilled over sodium and acetonitrile was distilled 
over CaH2 prior to use. Reagents were purchased of the highest commercial quality and 
used without further purification unless otherwise stated. Thin layer chromatography 
(TLC) was performed using Dynamic Adsorbents Inc. UV active silica gel, 200 µm, plastic 
backed plates on Dynamic Adsorbents Inc. UV active alumina N, 200 µm, F254 plastic 
backed plates. Flash and gravity chromatography were performed using silica gel P60A, 
40-63 µm purchased from Silicycle. Proton (1H NMR) and carbon high resolution nuclear 
magnetic resonance spectra (13C NMR) were obtained on a Bruker 300-MHz or a GE 500-
MHz NMR spectrometer. 1H NMR data are reported as follows: chemical shift, multiplicity 
(s = singlet, d = doublet, t = triplet, q = quartet, dd = doublet of doublets, dt = doublet of 
triplets, ddd = doublet of doublet of doublet, td = triplet of doublets, qd = quartet of 
doublets, sex = sextet, m = multiplet), integration, and coupling constants (Hz). 13C NMR 
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data are reported in parts per million (ppm) on the δ scale. The low resolution mass spectra 
(LRMS) were obtained as electron impact (EI, 70eV), which were recorded on a Hewlett-
Packard 5985B gas chromatography-mass spectrometer, while high resolution mass 
spectra (HRMS) were recorded on a VG Autospec (Manchester, England) mass 
spectrometer. HRMS recorded by electrospray ionization (ESI) methods were performed 
at the Laboratory for Biological Mass Spectrometery at Texas A&M University on an API 
QStar Pulsar model, manufactured by MDS Sciex.   
4-Methyl-3,4-dihydro-1H- benzo[e][1,4]diazepine-2,5-dione(12): A mixture of isatoic 
anhydride 11 (20g, 101 mmol) and sarcosine (9.02g, 101 mmol) in DMSO (160mL) was 
heated at 150°C for 5 hr, after which the solution was cooled to rt and poured into ice water 
(750mL) to furnish a light brown solid. This solid was collected by filtration, washed with 
water (3x200mL) and dried. The benzodiazepine 12 was obtained as a light brown solid 
(19g, 84%). This material was used directly in the next experiment. 
7-Bromo-4-methyl-3,4-dihydro-1H-benzo[e][1,4]diazepine-2,5-dione(13): 
Benzodiazepine 12 (32.4g, 0.17mol) was added to a solution of acetic acid (400mL) in a 
3-neck reaction flask. Sodium acetate (27.9g, 0.34mol) was added to this solution. Bromine 
(13.1mL, 0.255mol) was added using an addition funnel and the solution which resulted 
was allowed to stir for 18h and then poured into ice water (200mL) to provide a white solid. 
This solid was collected by filtration and then washed (3x200mL) and dried (Na2SO4). The 
bromobenzodiazepine 13 (36.6g, 80%) was used directly in the next experiment. mp 240-
242 °C; 1H NMR (DMSO-d6, 300MHz) δ10.54 (br s, 1H), 7.81 (d, 1 H, J = 2.2 Hz), 7.67 
(dd, 1 H, J = 2.4,8.6 Hz), 7.04 (d,l H,J = 8.7 Hz),3.87 (s,2 H),3.09 (s,3 H); MS (CI) m/z 
269 (M + H). 
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tert-Butyl-8-bromo-5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4] 
benzodiazepine-3-carboxylate (14): The t-BuOK (7.50 g, 66.91 mmol) was added to a 
solution of benzodiazepine 13 (15 g, 55.76 mmol) in anhydrous THF (1500 mL) at 0°C 
and the mixture which resulted was stirred for 20 min. The reaction mixture was cooled to 
–35 °C and diethyl chlorophosphate (10.47 mL, 72.48 mmol) was added slowly. After 
stirring at 0°C for 30 min the mixture was cooled to –78°C and t-butyl isocyanoacetate 
(8.926 mL, 61.33 mmol) was added, and this was followed by the addition of t-BuOK 
(6.88g, 61.33 mmol) at -78°C. After stirring at rt for 4 h the reaction was quenched with a 
saturated aq NaHCO3 solution (500 mL) and extracted with EtOAc (3 × 1000 mL). The 
combined organic layers were dried (Na2SO4) and concentrated to give a solid residue. This 
solid residue was triturated with Et2O (250 mL) and the ester 14 precipitated as an off-
white solid. The mother liquor was further purified by flash chromatography on silica gel 
(gradient elution 40– 60% EtOAc in hexane) to afford additional ester 14 in a combined 
yield of (15.3g, 70%). mp 180-183 °C; 1H NMR (CDCl3, 300MHz) δ 8.33 (s, 1H), 7.90 
(s, 1H), 7.62 (d, 1H, J =10.8 Hz), 7.03 (d, 1H, J = 8.6 Hz), 4.71 (br, s, 1H), 4.13 (br, s, 
1H), 3.10 (s, 3H), 1.56 (s, 9H); MS (EI) m/e 394 (M+, 100).  
tert-Butyl-8-(trimethylsilyl)-acetylene-5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5-
a][1,4]benzodiazepine3-carboxylate (6): A mixture of imidazobenzodiazepine 14 (7.5g, 
19.12mmol) was dissolved in dry triethyl amine (223mL ) and acetonitrile (149mL; 3:2 
ratio). This mixture was degassed under argon three times. To this degassed mixture, bis 
(triphenylphosphine)-palladium (II) acetate (1g, 7 mol %) was added. The mixture was 
again degassed (with vacuum) three times under argon. Trimethylsilyl acetylene (5.52mL, 
38.24mmol) was added and this reaction mixture was heated to reflux for 8h under argon. 
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The reaction mixture was cooled to rt and the solvents were concentrated under reduced 
pressure. This concentrated mixture was dissolved in ethyl acetate and passed through a 
bed of celite. After the removal of solvent under reduced pressure the residue was purified 
by flash chromatography (silica gel, EtOAc) to afford a yellow solid of RY-23 (6) (6.5g, 
83%). mp 199-200 °C. IR (KBr) 2971, 2156, 1723, 1662, 1500 cm -1 ; 1H NMR (CDCl3, 
300MHz) δ 8.13 (s, 1H), 7.84 (s, 1H), 7.64 (d, 1H, J = 8.2 Hz), 7.32 (d, 1H, J = 8.2 Hz), 
5.11 (br, 1H), 4.31 (br, 1H), 1.63 (s, 9H), 0.25 (s, 9H); MS (EI) m/e 409 (M+, 4), 354 (19), 
353 (82), 335 (45), 307 (100), 279 (23), 251 (16), 143 (13), 160 (21), 107 (14); Anal. Calcd 
for C22H27N3O3Si: C, 64.52; H, 6.64; N, 10.26; Found C, 64.57; H, 6.70; N, 10.46. The 
spectral data for 6 were in excellent agreement with the literature.54   
tert-Butyl-8-acetylene-5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5- 
a][1,4]benzodiazepine3-carboxylate (7): A solution of 20 (1.2g, 2.93 mmol) in THF 
(360mL) was treated with a solution of TBAF solution (1.0M in THF; 3.52mL,3.51mmol) 
at -30°C. The mixture which resulted was allowed to stir for 30 min at rt, after which the 
mixture was added to H2O (50mL) and extracted with EtOAc (3x100mL). The combined 
organic extracts were washed with brine (50mL) and dried (Na2SO4). After removal of the 
solvent under reduced pressure, the residue was purified by a wash column (silica gel, 
EtOAc) to give 7 (RY-24) as a yellow solid (0.89g, 90%): mp 213-214 °C. 1H NMR 
(CDCl3, 300MHz) δ 8.16 (s, 1H), 7.85 (s, 1H), 7.69 (d, 1H, J = 8.3 Hz), 7.35 (d, 1H, J = 
8.3 Hz), 5.15 (br, 1H), 4.32 (br, 1H), 3.23 (s, 3H), 3.20 (s, 1H), 1.63 (s, 9H); MS (EI) m/e 
337 (M+, 2), 282(15), 281 (78), 264 (31), 263(56), 235 (100), 229(22), 207 (36), 138 (16), 
101(19); Anal. Calcd for C19H19N3O3: C, 67.64; H, 5.68; N, 12.45; Found C, 67.50; H, 
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5.78; N, 12.41. The spectral data for 7 were in excellent agreement with the reported 
values.54 
7-Chloro-4-methyl-3,4-dihydro-1H-benzo[e][1,4]diazepine-2,5-dione (16): A mixture 
of 5-chloroisatoic anhydride 15 (20g, 101mmol) and sarcosine (9.02g, 101mmol) in DMSO 
(160mL) was heated at 150°C for 5 hr, after which it was cooled to rt and poured into ice 
water (750mL) to furnish a light brown solid. This solid was collected by filtration, washed 
with water (3x200mL) and dried (Na2SO4). The benzodiazepine 16 was obtained as a light 
brown solid (19g, 84%). This material was used directly in the next experiment. 
Ethyl-8-chloro-5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5-][1,4]benzodiazepine3-
carboxylate (17): t-BuOK (8.99 g, 80.14 mmol) was added to a solution of amide 16 (15 
g, 66.77 mmol) in anhydrous THF (1500 mL) at 0 °C and the solution allowed to stir for 
20 min. The reaction mixture which resulted was cooled to –35 °C and diethyl 
chlorophosphate (12.48 mL, 86.80 mmol) was added slowly. After stirring at 0 °C for 30 
min, the mixture was cooled to –78 °C and ethyl isocyanoacetate (8.03 mL, 73.44mmol) 
was added and this was followed by the addition of t-BuOK (8.24g, 73.44mmol). After 
stirring at rt for 4 h, the reaction mixture was quenched with a saturated aq solution of 
NaHCO3 (500 mL) and extracted with EtOAc (3 × 1000 mL). The combined organic layers 
were dried (Na2SO4) and concentrated to give a solid residue. This solid residue was treated 
with Et2O (250 mL) and the ester 17 was precipitated as an off-white solid. The mother 
liquor was further purified by flash chromatography on silica gel (gradient elution, 40– 
60%, EtOAc in hexane) to afford additional ester 17 with an overall yield of (19g, 89%). 
mp 192-193 °C; 1H NMR (CDCl3, 300MHz) δ 8.1 (d, 1H, J = 2.4 Hz), 7.90 (s, 1H), 7.62 
(dd, 1H, J = 8.7, 2.5 Hz), 7.40 (d, 1H, J = 8.6 Hz), 5.23 (br, s, 1H), 4.46 (q, 2H, J=7.12Hz), 
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4.13 (br, s, 1H), 3.27 (s, 3H), 1.47 (t, 3H, J=7.12Hz); MS (EI) m/e 319 (M+, 100). The data 
for this material were identical to the published values.14 
8-Chloro-5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5-α][1,4]benzodiazepine-3- 
methyl alcohol (18). A solution of imidazobenzodiazepine 17 (5 g, 15.6 mmol) in a 
mixture of ethyl ether (50 mL), and THF (50 mL) was stirred with LiBH4 (2.0 M in THF, 
9 mL, 18 mmol). The mixture which resulted, was then heated to reflux for 30 min, after 
which it was cooled to rt and treated with a saturated aq solution of NaHCO3 (5 mL). The 
solvent was concentrated and the residue was taken up in EtOAc (100 mL). The organic 
layer was washed with water (2 × 20 mL), brine (20 mL) and dried (MgSO4). After removal 
of the solvent under reduced pressure the residue was purified by flash chromatography 
(silica gel, EtOAc) to afford alcohol 18 as colorless crystals (2.9 g, 67%): mp 252-253 °C; 
IR (KBr) 3500 (br, OH), 3100, 1667, 1612, 823 cm-1; 1H NMR (CDCl3, 300MHz) δ 8.00 
(d, 1H, J = 2.4 Hz), 7.80 (s, 1H), 7.55 (dd, 1H, J = 8.7, 2.4 Hz), 7.30 (d, 1H, J = 8.6 Hz), 
4.70 (d, 2H, J = 4.2 Hz), 4.40 (s, 2H), 3.20 (s, 3H); MS (EI) m/e 279 (M+, 41), 277 (M+, 
100), 259 (84), 246 (55), 231(41). The data for this material were identical to the published 
values.15 
Methyl(8-chloro-5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5-α][1,4] benzodiazepin-
3-yl)methyl ether (19). The alcohol 18 (3g, 11 mmol) was dissolved in DMSO (56 mL) 
and KOH (2.41g, 44 mmol) was added to it. The mixture which resulted was stirred for 2-
3 minutes and then excess CH3I added to it. Then the reaction mixture was stirred for 5-10 
min and poured into ice water (100 mL) after which it was extracted with EtOAc (3 × 100 
mL). The combined organic extracts were washed with brine (50mL) and dried (MgSO4). 
After the removal of solvent under reduced pressure, the residue was purified by a wash 
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column on silica gel (EtOAc) to give ether 19 (PWZ- 029) as an off-white powder (2.83g, 
90%): mp 193-194 °C; IR (KBr) 3122, 2973, 1632, 1611, 811 cm-1; 1H NMR (CDCl3, 
300MHz) δ 8.00 (d, 1H, J = 2.4 Hz), 7.80 (s, 1H), 7.55 (dd, 1H, J = 8.7, 2.5 Hz), 7.30 (d, 
1H, J = 8.6 Hz), 4.55 (br, 2H), 4.38 (s, 2H), 3.42 (s, 3H), 3.18 (s, 3H). The spectral data 
for this material were identical to the published values86. 
8-Chloro-5-methyl-6-Oxo-5,6-dihydro-4H-benzo-[f]-imidazo-[1,5-a]-[1,4]-dizaepine-
3-carboxylic acid (20). The ester 17 (2 g, 6 mmol) was dissolved in EtOH (150 mL) to 
form a solution and then 10% aq sodium hydroxide solution (40 mL) was added to the 
mixture. The mixture was heated to reflux for 0.5 h and the EtOH was removed under 
reduced pressure, after which the solution was allowed to cool. The pH was then adjusted 
to 4 by adding cold 10% aq HCl dropwise. The solid which precipitated was filtered and 
the solid acid which was isolated was washed with water and ether. The solid was dried to 
provide acid 20: mp >260oC; IR (neat) 3100, 2424, 1661, 1642, 1562 cm-1; 1H NMR 
(300 MHz, DMSO) δ 8.35 (s, 1H), 7.77-7.88 (m, 3H), 5.28 (br s, 2H), 4.55 (br s, 2H), 3.09 
(s, 3H); MS (EI) m/e (relative intensity) 291 (M+, 44), 273 (61), 245 (100), 230 (47), 217 
(62), 75 (37). Anal. Calcd. for C13H10ClN3O3. 0.3CH2Cl2: C, 50.57; H, 3.37; N, 13.32. 
Found: C, 50.64; H, 3.25; N, 13.12. 
3-(Bromomethyl)-8-chloro-5-methyl-4H-benzo[f]imidazo[1,5-a][1,4]diazepin-6(5H)-
one (21). The alcohol 18 (500mg, 1.80mmol) was dissolved in anhydrous CH2Cl2 
(100mL). To this mixture, a solution of PBr3 (0.378 mL, 3.61mmol) was added at °C and 
the reaction was allowed to stirred for 2h. The reaction mixture was then quenched with a 
saturated aq solution of Na2CO3 and extracted with CH2Cl2. The combined organic layers 
were washed with brine and dried (MgSO4). The solvent was removed under reduced 
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pressure to afford bromide analog (21) as a white powder 80%. 1H NMR (CDCl3, 
300MHz) δ 8.05 (d, 1H, J = 2.3Hz), 7.83 (s, 1H), 7.59 (dd, 1H, J = 2.39 Hz, 6.23 Hz), 7.35 
(d, 1H, J = 8.25Hz), 4.60 (br, s, 2H), 4.38 (br, s, 2H), 3.10 (s, 3H). 13C NMR (75 MHz, 
CDCl3): δ 165.38, 134.79, 134.54, 134.15, 132.75, 132.61, 131.11, 130.14, 127.59, 123.11, 
42.32, 36.12, 24.26. HRMS (ES+) calculated for C13H11ClN3O: 260.0591; found: 
260.0586. This material was used in a later step. 
8-chloro-3-((ethylthio)methyl)-5-methyl-4H-benzo[f]imidazo[1,5-a][1,4]diazepin-
6(5H)-one (22). The bromide 21 (100mg, 2.96mmol) was dissolved in DMF (1.5mL) at rt. 
In a separate flask, NaH (70mg, 2.9mmol) was dissolved in CH3CH2SH (220mg, 
3.54mmol). The solution of NaH and CH3CH2SH which resulted was added to the bromide 
and the reaction mixture was stir overnight. The reaction mixture was then quenched with 
water and extracted with ethyl acetate. The combined organic layers were washed with 
brine and dried (MgSO4). The solvent was removed under reduced pressure and the residue 
was purified by flash chromatography on silica gel (gradient elution 40-60% EtOAc : 
hexane) to afford 22 with an overall yield of 80%. 1H NMR (CDCl3, 300MHz) δ 8.40 (d, 
1H, J = 2.4Hz), 7.80 (s, 1H), 7.55 (dd, 1H, J = 8.3 Hz, 2.39 Hz), 7.34 (d, 1H, J = 8.6Hz), 
4.40 (s, 2H), 3.82 (s, 3H), 2.62 (m, 2H), 1.32(t,3H). 13C NMR (75 MHz, CDCl3): δ 164.89, 
135.80, 133.86, 133.73, 132.61, 132.52, 131.42, 130.08, 126.38, 123.08, 42.40, 35.97, 
27.65, 26.01, 14.46 HRMS (ES+) calculated for C15H17ClN3OS: 322.0781, Found Mass: 
322.0770 
8-Chloro-5-methyl-3-((methylthio)methyl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepin-
6(5H)-one (23). The bromide 21 (200mg, 0.587mmol) was dissolved in DMF (20ml). To 
this mixture, NaSCH3 (411mg, 5.86mmol) was added and the reaction mixture was allowed 
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to stir overnight. The reaction mixture was then quenched with water and extracted with 
ethyl acetate. The combined organic layers were washed with brine and dried (MgSO4). 
The solvent was removed under reduced pressure and the residue was purified by flash 
chromatography on silica gel (gradient elution 3:2 EtOAc : hexane) to afford 23 (PB-I-
056) with an overall yield of 85%. 1H NMR (CDCl3, 300MHz) δ 8.04 (d, 1H, J = 2.4Hz), 
7.89 (s, 1H), 7.58 (d, 1H, J = 8.4, 2.4 Hz), 7.35 (d, 1H, J = 8.4Hz), 4.45 (s, 2H), 3.8 (s, 
2H), 3.28 (s, 3H), 2.23(s, 3H). 13C NMR (75 MHz, CDCl3): δ 165.60, 135.59, 133.86, 
133.73, 132.61, 132.52, 131.47, 130.08, 126.38, 123.08, 42.36, 35.92, 29.98, 15.54. 
HRMS (ES+) calculated for C14H15ClN3OS: 308.0624, Found Mass: 308.0620. 
S-ethyl-8-chloro-5-methyl-6-oxo-5,6-dihydro-4H-benzo[f]imidazo[1,5a][1,4] 
diazepine-3-carbothioate (24). The acid 20 (100mg, 0.297mmol) was dissolved in dry 
CH2Cl2 (20mL) at room temperature, excess SOCl2 was added in one portion. The reaction 
mixture was heated to reflux for 2h until analysis of the mixture by TLC indicated the 
absence of starting material. The reaction mixture was concentrated under reduced pressure 
on a rotavapor a few times with CH2Cl2 to remove the excess SOCl2 and dried under 
vaccum. The solid which resulted was stir in dry CH2Cl2 (20 mL) at 0°C. To this reaction 
mixture, Et3N (0.5) and CH3CH2SH (0.185mg, 2.97mmol) were added and allowed to stir 
overnight. The mixture which resulted was then quenched with H2O. The combined 
organic layers were washed with brine and dried MgSO4. After the removal of the solvent 
under reduced pressure, the residue was purified by flash chromatography on silica gel 
(gradient elution 3:2 EtOAc : hexane) to afford 24 (PB-I-059) in an overall yield of  70%. 
1H NMR CDCl3, 300MHz) δ 8.07 (d, 1H, J = 2.19Hz), 7.88 (s, 1H), 7.62 (d, 1H, J = 2.4, 
6.2 Hz), 7.39 (d, 1H, J = 8.5Hz), 5.19 (br, s,1H), 4.38 (br,s, 1H), 3.25 (s, 3H), 3.07(m, 2H), 
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1.38(t,3H). 13C NMR (75 MHz, CDCl3): δ188.33, 165.18, 134.91, 134.52, 132.79, 132.69, 
131.41, 130.54, 130.17, 123.21, 42.03, 36.17, 22.64, 14.66. HRMS (ES+) calculated for 
C15H15ClN3O2S: 336.0574, Found Mass: 336.059. 
S-Methyl8-chloro-5-methyl-6-oxo-5,6-dihydro-4H-benzo[f]imidazo[1,5-a][1,4] 
diazepine-3-carbothioate (25). The acid 20 (100mg, 0.297mmol) was dissolved in dry 
CH2Cl2 (20mL) at room temperature, excess SOCl2 was added in one portion. The reaction 
mixture was heated to reflux for 2h until analysis of the mixture by TLC indicated the 
absence of starting material. The reaction mixture was concentrated under reduced pressure 
on a rotavapor a few times with CH2Cl2 to remove the excess SOCl2 and dried under 
vaccum. The solid which resulted was stir in dry CH2Cl2 (20 mL) at 0°C. To this reaction 
mixture, NaSCH3 (82mg, 1.2mmol) was added and allowed to stir overnight. The mixture 
which resulted was then quenched with H2O. The combined organic layers were washed 
with brine and dried MgSO4. After the removal of the solvent under reduced pressure, the 
residue was purified by flash chromatography on silica gel (gradient elution 3:2 EtOAc : 
hexane) to afford 25 (PB-I-060) in an overall yield of 75%. 1H NMR (CDCl3, 300MHz) 
δ 8.08 (d, 1H, J = 2.1Hz), 7.90 (s, 1H), 7.63 (d, 1H, J = 8.03 Hz), 7.40 (d, 1H, J = 8.45Hz), 
5.20 (br, s, 1H), 4.37 (br, s, 1H), 3.26 (s, 3H), 2.48 (S, 2H). 13C NMR (75 M 
Hz, CDCl3): δ 188.71, 165.19, 134.93, 134.58, 132.79, 132.71, 131.34, 130.55, 123.19, 
42.02, 36.18, 11.03. HRMS (ES+) calculated for C14H13ClN3O2S: 322.0417, Found Mass: 
322.0446.  
8-Chloro-3-(isopropoxymethyl)-5-methyl-4H-benzo[f]imidazo[1,5-a][1,4]diazepin-
6(5H)-one (26). To a slurry of NaH (84mg, 3.5mmol) in 2-propanol (4.5 ml) at rt was 
added to bromide 21 (100mg, .304mmol). The reaction mixture was allowed to stirr for 3hr 
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at rt and then quenched with water. The combined organic layers were washed with brine 
and dried MgSO4. After the removal of the solvent under reduced pressure, the residue was 
purified by flash chromatography on silica gel (gradient elution 4:1 EtOAc: hexane) to 
afford 26 (PB-I-061) with an overall yield of 75%. 1H NMR (CDCl3, 300MHz) ) δ 8.04 
(d, 1H, J = 2.39Hz), 7.81 (s, 1H), 7.56 (d, 1H, J = 8.4,2.4 Hz), 7.35 (d, 1H, J = 8.4Hz), 
4.61 (s, 2H), 3.8 (m, 1H), 3.28 (s, 3H), 1.267(d, 9H, J = 5.8) 13C NMR (75 MHz, CDCl3): 
δ165.61, 135.92, 133.94, 133.61, 132.52, 132.43, 131.47, 130.24, 127.02, 123.05, 71.70, 
64.23, 42.42, 35.53, 29.68, 22.13. HRMS (ES+) calculated for C16H19ClN3O2: 320.1166, 
Found Mass: 320.1189. 
8-Chloro-5-methyl-3-((methylselanyl)methyl)-4H-benzo[f]imidazo[1,5-
a][1,4]diazepin-6(5H)-one (27). The bromide 21 (100mg, 0.30mmol) was dissolved in 
THF (10mL). In a separate flask, NaBH4 (70mg, 2.9mmol) was dissolved in CH3SeCH3 
(55mg, .293mmol). The solution which resulted was added to the bromide and the reaction 
mixture was stir overnight. The reaction mixture was then quenched with water and 
extracted with ethyl acetate. The combined organic layers were washed with brine and 
dried (MgSO4). The solvent was removed under reduced pressure and the residue was 
purified by flash chromatography on silica gel (gradient elution 40-60% EtOAc : hexane) 
to afford selenium  analog 27 in an overall yield of 60%. 1H NMR (CDCl3, 300MHz) ) δ 
8.08 (d, 1H, J = 2.0Hz), 7.98 (s, 1H), 7.66 (d, 1H, J = 6.60, 1.88 Hz), 7.42 (d, 1H, J = 
8.4Hz), 5.164 (s, 2H), 4.46 (s, 1H), 3.25 (s, 3H), 2.19 (s, 2H) , 1.27 (S,3H). 13C NMR (75 
MHz, CDCl3): δ188.13, 165.14, 135.62, 135.16, 132.87, 132.76, 130.63, 129.90, 123.23, 
41.77, 36.26, 30.92, 29.70. HRMS (ES+) calculated for C14H15ClN3OSe: 356.0069, Found 
Mass: 356.0071. 
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8-Chloro-N-cyclopropyl-5-methyl-6-oxo-5,6-dihydro-4H-benzo[f]imidazo[1,5- 
a][1,4]diazepine-3-carboxamide (28). The acid 20 (100mg, 0.297mmol) was dissolved in 
dry CH2Cl2 (20mL) at room temperature and excess SOCl2 was added in one portion. The 
reaction mixture was heated to reflux for 2h until analysis of the mixture by TLC indicated 
the absence of starting material. The reaction mixture was concentrated under reduced 
pressure on a rotavapor and flash evaporated a few times with CH2Cl2 to remove the excess 
SOCl2 and dried under vaccum. The solid which resulted was stirred in dry CH2Cl2 (20 
mL) at 0°C. To this reaction mixture, cyclopropylamine (1ml, 4.45mmol) and 
triethylamine (0.5ml) were added and the mixture allowed to stir overnight. The mixture 
which resulted was then quenched with CH3Cl2. The combined organic layers were washed 
with brine and dried MgSO4. After the removal of the solvent under reduced pressure, the 
residue was purified by flash chromatography on silica gel (gradient elution 3:2 EtOAc: 
hexane) to afford 27 (PB-I-076) with an overall yield of 92%. 1H NMR (CDCl3, 300MHz) 
) δ 8.054 (d, 1H, J = 2.4Hz), 7.832 (s, 1H), 7.59 (dd, 1H, J = 8.7,2.4 Hz), 7.80 (d, 1H, J = 
2.1Hz), 5.42 (br, s,1H), 4.33 (br,s, 1H), 3.20 (s, 3H), 2.88(m, 1H), 0.86(m,2H), .675(m,2H) 
13C NMR (75 MHz, CDCl3): δ 165.31, 163.79, 134.52, 133.44, 132.63, 132.59, 132.36, 
130.99, 130.65, 130.50, 123.04, 42.05, 36.10, 22.12, 6.49 HRMS (ES+) calculated for 
C15H16ClN4O2: 319.0962, Found Mass: 319.0847. 
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             8. Computer Modeling Methods 
The core structures of the ligands were taken from available X-ray crystallographic 
coordinates or generated using the SYBYL fragment library.85 The structures which 
resulted were energy minimized using MM2 (molecular mechanics program 2) or MMFF 
(Merck molecular force field), and the subsequent Monte Carlo conformational searches 
were carried out on MacroModel 6.0 on a Silicon Graphics Personal Iris 4D/35 workstation 
or a Silicon Graphics Octane SI 2P 175 R10000 workstation, respectively. The low energy 
conformations were then fully optimized via molecular orbital calculations at the 3-21G 
basis set with torsional angles fixed. The structures which resulted were further calibrated 
with 6-31G* single point calculations at an “SCF=TIGHT” convergence criteria via 
Gaussian 9216588 on a Silicon Graphics Indigo R4400 workstation, or Gaussian 9416688 
on a Silicon Graphics Octane SI2P175R10000 workstation.39 
9. Competition Binding Assays (With Dr. Majumder and Dr. Roth). 
Competition binding assays were performed in a total volume of 0.5 mL at 4 °C for 1 h 
using [3H] flunitrazepam as the radiolabel. A total of 6 μg of cloned human GABAA 
receptor DNA containing the desired α subtype along with the β2 and γ2 subunits were 
used for transfecting the HEK 293T cell line using Fugene 6 (Roche Diagnostic) 
transfecting reagent. Cells were harvested 48 h after transfection, washed with Tris-HCl 
buffer (pH 7.0) and Tris Acetate buffer (pH 7.4) and the resulting pellets were stored at - 
80 °C until assayed. On the day of the assay, pellets containing 20-50 μg of GABAA 
receptor protein were resuspended in (50 mM Tris-acetate pH 7.4 at 4 °C) and incubated 
with the radiolabel as previously described.90 Nonspecific binding was defined as 
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radioactivity bound in the presence of 100 μM diazepam and represented less than 20% of 
total binding. Membranes were harvested with a Brandel cell harvester followed by three 
ice-cold washes onto polyethyleneimine-pretreated (0.3%) Whatman GF/C filters. Filters 
were dried overnight and then soaked in Ecoscint A liquid scintillation cocktail (National 
Diagnostics; Atlanta, GA). Bound radioactivity was quantified by liquid scintillation 
counting. Membrane protein concentrations were determined using an assay kit from Bio-
Rad (Hercules, CA) with bovine serum albumin as the standard. 
10. CANTAB work (Rowlett and Cook et al.)83: Preferential inverse 
agonist action at α5GABAA receptors resulted in enhancement of 
performance on memory tasks. 
10.1 Subjects: Experiments were conducted with adult male rhesus monkeys (Macaca 
mulatta), aged 10-15 years (corresponding roughly to “middle aged” monkeys), born and 
reared at the New England Primate Research Center breeding facility. The monkeys were 
experimentally naïve at the beginning of the study. Monkeys were prepared with a non-
allergic nylon vest (Lomir) and seated in primate chairs (Crisp Instruments) enclosed in 
ventilated, sound-attenuating chambers (Med Associates); or prepared with the non-
allergic nylon vest attached to a flexible, stainless steel tether (Lomir) connected to the top 
of the monkey's home cage. The restraint chair system was used in CANTAB studies, and 
the tether system was used in ORD, observational and MAP studies. All monkeys were 
housed in a temperature- and humidity-controlled housing room and maintained on a 12-
hr on/12-hr off light/dark schedule (lights on at 0600 hr). Water was available continuously 
in the home cage. 
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10.2 Food availability: The protocol for food restriction developed by Taffe (2004) 
was used. Briefly, the monkeys in all studies were weighed weekly, and these weights were 
used to calculate food (LabDiet 5038) allotments based on metabolic energy requirements 
for rhesus monkeys. The calculation was based on the equation: y=15.504x-0.8219, in which 
y=food biscuits/kg/day and x=body weight in kg (Taffe 2004). Monkeys were maintained 
at 100% of this allotment for at least 3 weeks or until weights were stable (no upward or 
downward trend over three weight determinations). Once stable, the monkeys’ food 
allotments were gradually reduced to 70 to 85% (note that this was not a reduction in 
weight, rather a reduction in food allotment), an amount shown to result in stable and 
accurate performance in CANTAB tasks. Weekly weighing occured throughout the studies 
to adjust feeding (within the 70-85% range) based on a combination of weight, 
performance, and overall health (as determined by routine physical exams conducted by 
the Clinical Veterinary Staff). 
10.3 Surgery and drug delivery: All compounds were administered via the 
intravenous (i.v.) route. We used this route in order to minimize pharmacokinetic variables 
and to allow direct comparisons with other procedures at Harvard Medical School 
(NERPC) designed to study BZ effects in rhesus monkeys (e.g., i.v. self-administration 
models of abuse potential). Monkeys were implanted with venous catheters using the 
surgical procedures described by Platt et al. (2005). Surgery was conducted under aseptic 
conditions using isoflurane/oxygen anesthesia. Catheters were passed by way of a jugular, 
femoral or brachial vein to the level of the right atrium. The distal end of the catheter was 
passed subcutaneously to a mid-scapular exit point. Catheters were flushed routinely with 
saline containing Heparin (100-150 U/ml), and physical exams were conducted that 
46 
 
 
 
occasionally included contrast-dye infusion into the catheter, followed by X-ray to verify 
catheter patency and proper placement. Using these procedures, catheters can remain 
patent for up to 3 years. 
10.4 General design and data analyses: Separate groups of 6-8 monkeys were 
used in the CANTAB vs. the ORD/MAP/observation studies, with each monkey in a group 
receiving all treatments whenever possible. Dependent measures for the studies depended 
on the individual tasks, as described below. The studies employed within-subjects design, 
in which each subject serves as its own control. This design permits scientifically 
meaningful results to be obtained with fewer animals than would be required using most 
other approaches. For individual subject analysis, data during test sessions were compared 
to data from control sessions and significance of effects were determined on the basis of 
95% confidence intervals established under baseline conditions. For comparison of doses 
within individual tasks, repeated-measures ANOVAs were used to evaluate statistical 
reliability when warranted. For all studies, multiple comparisons were assessed for 
statistical reliability using a priori Bonferroni t-tests, when applicable. Comparisons of 
drug potencies were conducted by computing ED50 values (dose engendering 50% of the 
maximum effect). The ED50s were computed using non-linear regression analysis 
techniques. 
10.5 CANTAB Tasks in Monkeys.  
10.5.1 Apparatus: As described above, monkeys were trained to sit in primate chairs 
that were be placed in a sound-attenuating chamber. Inside this chamber were a computer-
controlled touch-screen monitor (Campden or Lafayette Instruments, Inc,), equipped with 
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a dispenser to deliver 190-mg flavored food pellets (BioServe, Inc.). Experimental events 
were controlled by the CANTAB software system on a computer in an adjacent room. 
10.5.2 Delayed non-matching to sample (DNMS). The DNMS task was a short-
term recognition memory task involving sets of visual discriminations. A sample stimulus 
is presented in the center of the screen, and the animal must touch this stimulus within 30 
sec. After a touch, the screen was blanked and following a variable retention interval, two 
stimuli were presented on the lower left and right of the screen. The retention interval 
consisted of 0, 1, 3, or 10 min; if performance was highly variable, the delays were adjusted 
for individual monkeys based on performance such that short, medium, and long delays 
were tested. Of the two “matching” stimuli, one stimulus was identical to the sample 
stimulus (“matching” stimulus) and the other was novel (“non-matching” stimulus). A 
touch directed to the non-matching stimulus was followed by reinforcer delivery. In 
addition to the four retention interval conditions, a simultaneous condition was included in 
which the sample stimulus remained present while the matching and non-matching stimuli 
were present. A session consisted of 10 trials of each retention interval, presented in a 
randomly intermixed fashion (total trials=50). The CANTAB software used 469 shapes 
and 7 colors to ensure that discriminations were unique for approximately 120,000 trials. 
The primary dependent measured for the DNMS task are the percent correct responses at 
each delay and the latency to respond at each delay. The number of trials completed also 
was recorded as a measure of motivation and/or ability to perform the task. 
10.5.3 Paired associated learning (PAL). Large colored abstract stimuli were 
displayed in one of 4 positions (top center, bottom center, left middle, right middle). The 
subject was required to touch the sample stimulus, which then disappeared. After a 1-sec 
48 
 
 
 
delay, the same pattern reappears (choice phase) in two or more locations on the screen 
(the original location plus one or more novel locations). The subject was required to touch 
the stimulus that was presented in the same location as the sample item to obtain a food 
pellet. Task difficulty was increased by increasing the number of stimulus-location 
associations required on each trial. Training was initiated with sessions that present 25 1-
stimulus trials and 25 2-stimulus trials until performance averaged >50% correct trials on 
the 2-stimulus trials. Next, monkeys received sessions of 25 2-stimulus trials and 25 3-
stimulus trials until performance averaged >25% correct trials on the 3-stimulus trials. This 
part of the PAL task measured memory for stimulus-location associations. Next, a learning 
component is introduced in which a trial repeats if a mistake was made in attempting to 
complete this trial (i.e. the monkey gets 0-2 of 3 stimulus-locations correct in a 3-stimulus 
trial). Up to 6 attempts at a given trial were allowed. Finally, 4-stimulus trials were added 
when performance of 3-stimulus trials exceeded 50% correct (thus, the PAL task measured 
both memory and learning of stimulus-location associations). The dependent measures 
were the percent correct at each difficulty level and the latencies to respond. 
10.5.4 Intradimensional/extradimensional set shifting (ID/ED). The ID/ED 
shift task evaluated the ability of a subject to attend to specific attributes of a stimulus, as 
well as the ability to shift attention to other attributes when required. This task consisted 
of a series of eight discrimination learning stages wherein touching only one of two stimuli 
presented on the screen resulted in food pellet delivery. Within any given stage of the task, 
a pair of stimuli was presented and the same stimulus was associated with reinforcement 
(S+ stimulus) until the performance criteria were met (18 of 20 consecutive trials correct). 
Correct choices must be made within 30 sec, and following a correct choice the screen was 
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blanked for 5 sec while an incorrect choice (S- stimulus) resulted in a 0.2 sec tone and a 9-
sec period of blank screen. The task consisted of 4 levels of stimulus sets, each 
progressively more difficult. In the first stimulus set (Level 1), two distinctly shaped stimuli 
were presented, with touches on one shape resulting in food pellet delivery. This level (and 
all subsequent levels) included a stimulus reversal, in which the same two shapes are 
retained but pressing the S+ stimulus now does not result in reinforcement, whereas 
touching the former S- stimulus did result in food pellet delivery. In Level 2, a compound 
discrimination was presented. For this discrimination, the two shapes from Level 1 are 
present, but additional stimuli, consisted of lines, were superimposed onto the existing 
shapes. Because the shape discrimination from the previous stage did not change, the lines 
are irrelevant to this discrimination. Level 3 consisted of the intra-dimensional (ID) shift 
stage. For this discrimination, two new shapes with new lines were presented. This was 
considered an ID shift due to the fact that despite new shapes and lines being introduced, 
the shape remained the relevant dimension for the discrimination. In the final level, the 
extra-dimensional (ED) shift will be introduced. Thus, in Level 4, new shapes and lines 
were presented; however, the lines—not the shape—were the relevant discriminative 
stimulus. Performance was determined as the number of errors at each stage, and the data 
were subjected to a square root transformation to achieve normal distributions. 
10.5.5 Progressive-Ratio (PR). PR procedures consisted of response requirements 
that progressively increased across a session until responding ceases. The last response 
requirement completed, termed “break point”, provided a quantitative measure of the 
reinforcing effectiveness of a stimulus. For these studies, a session was initiated by a 
colored box appearing in the middle of the screen. Touching the box once resulted in food 
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pellet delivery, and the response requirement were progressively increased following each 
reinforcer by an incremental value beginning at 1 and doubling after 8 response 
requirements were completed successfully. Thus, the response requirement sequences 
consisted of: Increment= 1, response requirements= 1, 2, 3, 4, 5, 6, 7, 8; Increment = 2, 
response requirements = 10, 12, 14, 16, 18, 20, 22, 24; Increment = 4, response 
requirements = 28, 32, 36, 40, 44, 48, 52, 56; and so on. Sessions were a maximum of 30 
min, and were terminated if 3 min elapses without a response. Performance was measured 
as the break point and number of food pellets delivered per session. This procedure 
provided a measure of the ability of the animal to respond, as well as an assessment of 
“motivation” to perform. 
10.5.6 Training. Initial training began with shaping the basic response of touching the 
screen. A large colored square was displayed that occupied most of the screen. Touching 
the screen inside the box was a “correct” response and results in food reinforcement. With 
each correct response, the size of the square decreased until the monkey readily pressed a 
1-in box in any location on the screen. This initial training typically required up to 5 
sessions. Currently 4 monkeys were trained at various stages of the DNMS and ID/ED task. 
These monkeys initiated training on PAL (a task that requires a lengthy training period, 
Taffe et al. 2004) with “reminder” trials for DNMS and ID/ED scheduled one day per week. 
We anticipated approximately 5-6 more months of training for PAL performance to reach 
acceptable performance.  
For new monkeys, CANTAB training was initiated by gradually introducing different 
tasks, and also incorporate training on the ORD task. In the first phase of training, the PAL 
task was introduced 5 days/week. After approximately 6 months, the DNMS task was 
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introduced on days 1-4 of the week, with PAL training continuing on day 5. In our 
experience, DNMS training typically took up to 3 months, once criterion performance was 
met, DNMS training was initiated on days 1-3, with PAL training scheduled for days 4 and 
5, respectively. PAL training may take up to and over 12 months, therefore, after 9 months 
the ID/ED task was introduced into the sequence once or twice per week on randomly 
chosen days (this task did not require special training, Weed et al., 1999). In the final phase 
of training, two tasks per day were introduced and the PR schedule introduced according 
to the schedule: day 1: PR/PAL; day 2: DNMS/PR; day 3: PAL; day 4: DNMS/PR; day 5: 
ID/ED/PR. 
10.5.7 Testing. Once training criteria were reached on all tasks, the 8-day cycles shown 
in Table 4 were initiated. The two cycles shown in the Table allowed a dose of test 
compound and vehicle to be determined twice in all tasks. For each compound, vehicle 
plus at least 4 doses were evaluated. All doses of a compound (or dose of compound plus 
antagonist) were tested in irregular order, with a compound finished prior to moving to the 
next compound. A test session consisted of i.v. injections of compound(s) at an appropriate 
pretreatment time prior to the session. Based on the scheduling shown in Table 20, for 
CANTAB a dose-response function was required approximately 10 weeks to complete. 
Table 4: Schedule of CANTAB tests for a single dose of compound plus vehicle 
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11. Object Retrieval with Detours (ORD) Task. 
To augment CANTAB-based testing, parallel assessments were conducted using the ORD 
Task, which was a manual test sensitive to frontostriatal deficits (Taylor et al. 1990; Jentsch 
et al. 1999) and has been validated in pharmacological studies at NERPC. The task required 
the monkey to retrieve a small piece of palatable food from a transparent box that was open 
on one side only. The box was attached to a tray that can be positioned within easy reach 
of the monkey. Different levels of task complexity were achieved by varying the 
orientation of the open side of the box, the position of the box on the tray, and the position 
of the food relative to the opening. The level of cognitive complexity and motor difficulty 
of each task was rated a priori using the criteria of Taylor et al. (1990). The 12 task 
configurations varied from those characterized by high cognitive complexity/low motor 
difficulty to low cognitive complexity/high motor difficulty. Training on the ORD task 
typically required 14-21 sessions, and tests were scheduled as described above in Table 4. 
The primary dependent measure for the ORD task was “percent success”, which was the 
total number of reaches minus “incorrect” (i.e., a reach in which the food item was not 
obtained) and “barrier” reaches (i.e., a reach in which the monkey contacted a closed side 
of the box), divided by total reaches and then multiplied by 100. Barrier reaches were also 
analyzed separately as a measure of perseverative behavior, and reach latencies (i.e., time 
to obtain food or maximum trial length of 20 seconds) were recorded as a measure of motor 
impairment. 
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12. Assessment of Motor Coordination and Behavioral Effects in 
Monkeys. 
MAP apparatus and procedure. To evaluate fine motor coordination, monkeys were 
trained using the movement assessment panel (MAP) system developed by Gash and 
colleagues (Gash et al. 1999). The MAP (Quanteon, Inc.) consists of a Lexan® box 
attached to a clear Lexan® panel that was mounted on to home cage (Figure 14). Portals 
in the front panel and on the sides of the food receptacle allowed monkeys to retrieve small 
food objects (e.g., miniature marshmallows or raisins). Arrays of photocells are attached 
to the portals on the front panel (Portal A) and food receptacle (Portal B). The amount of 
time that the photobeams for Portal A were broken was considered a measure of gross 
motor coordination, whereas the amount of time that the photobeams for Portal B were 
broken was considered a measure of fine motor coordination (Gash et al. 1999). MAP 
studies occurred in the home cage of monkeys prepared with the tether system. The MAP 
apparatus fit the cage door, and monkeys received initial training by placing food treats in 
different parts of the apparatus until they consistently retrieved treats from the food 
receptacle. 
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Figure 23. Movement Assessment Panel for Rhesus Monkeys. 
Training occurred 5 days per week until latencies retrieved the treat are stable (no upward 
or downward trends over 3 consecutive sessions) and testing occurred on day 2 and day 5 
of this 5-day cycle. 
Observation studies. Observers were trained in the use of the behavioral scoring 
instrument developed in previous studies at NERPC. Each observer underwent at least 20 
hrs of observational training until they reached a > 90% reliability criterion based on 
percent agreement scores. The scoring system included 19 categories encompassing a wide 
range of species-typical and drug-induced behaviors including locomotion, environmental 
manipulation, foraging, self-grooming, scratching, stereotypic behavior such as self-
grasping, back flipping, and hair pulling, ataxia, sleep posture, moderate and deep sedation. 
These behavioral categories have proven to be useful for characterization of the sedative 
and motoric effects of BZ-type compounds in previous research at NERPC. Observation 
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studies occurred in the same monkeys that were trained on the MAP task. Observation 
studies were conducted in these monkeys in alternate weeks, on the 2nd and 3rd day of the 
5-day cycle (i.e., MAP testing occurred one week, observation tests occurred the following 
week, and so on). Video cameras were used to record the monkeys’ behavior during 
observation sessions. This provided an archival record of experimental sessions, permitted 
subsequent scoring of videotapes by independent observers, and eliminated the possibility 
that an observer’s presence disturbed the monkeys’ behavior. All behaviors were scored 
during 5-min sampling periods as described above. Each 5-min period was subdivided into 
twenty 15-s intervals, and frequency scores were calculated as the proportion of 15-s 
intervals in which a particular behavior occurred. Data was analyzed separately in 
individual subjects and for the group when appropriate used the statistical approach 
described earlier at NERPC. 
13. Experimental procedures for the electrophysiology (with Dr.R. 
Furtmüller and Dr. W. Sieghart)91-94 
Preparation of cloned mRNA 
Cloning of GABAA receptor subunits α1, β3 and γ2 into pCDM8 expression vectors 
(Invitrogen, CA) has been described elsewhere.96 GABAA receptor subunit α4 was cloned 
in an analogous way. cDNAs for subunits α2, α3 and α5 were gifts from P. Malherbe and 
were subcloned into a pCI-vector. cDNA for subunit α6 was a gift from P. Seeburg and 
was subcloned into the vector pGEM-3Z (Promega). After linearizing the cDNA vectors 
with appropriate restriction endonucleases, capped transcripts were produced using the 
mMessage mMachine T7 transcription kit (Ambion, TX). The capped transcripts were 
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polyadenylated using yeast poly (A) polymerase (USB, OH) and were diluted and stored 
in diethylpyrocarbonate-treated water at –70 °C. 
Functional expression of GABAA receptors 
The methods used for isolating, culturing, injecting and defolliculating of the oocytes were 
identical to those as described previously.95,91,97 Briefly, mature female Xenopus laevis 
(Nasco, WI) were anaesthetized in a bath of ice-cold 0.17 % Tricain (Ethyl-m-
aminobenzoate, Sigma, MO) before decapitation and removal of the frog ovary. Stage 5 to 
6 oocytes with the follicle cell layer around them were singled out of the ovary using a 
platinum wire loop. Oocytes were stored and incubated at 18 °C in modified Barths 
medium (MB, containing 88 mM NaCl, 10 mM HEPES-NaOH (pH 7.4), 2.4 mM NaHCO3, 
1 mM KCl, 0.82 mM MgSO4, 0.41 mM CaCl2, 0.34 mM Ca(NO3)2) that was supplemented 
with 100 U/mL penicillin and 100 μg/mL streptomycin. Oocytes with follicle cell layers 
still around them were injected with a total of 2.25 ng of cRNA. This solution contained 
the transcripts for the different α subunits and the β 3 subunit at a concentration of 0.0065 
ng/nL as well as the transcript for the γ2 subunit at 0.032 ng/nL. After injection of the 
cRNA, oocytes were incubated for at least 36 h before the enveloping follicle cell layers 
were removed. To this end, oocytes were incubated for 20 min at 37 °C in MB that 
contained 1 mg/mL collagenase type IA and 0.1 mg/mL trypsin inhibitor I-S (both Sigma). 
This was followed by osmotic shrinkage of the oocytes in doubly concentrated MB medium 
supplied with 4 mM Na-EGTA. Finally, the oocytes were transferred to a culture dish 
containing MB and were gently pushed away from the follicle cell layer which stuck to the 
surface of the dish. After removal of the follicle cell layer, oocytes were allowed to recover 
for at least 4 h before being used in electrophysiological experiments. 
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Electrophysiological experiment. 94,98 
For electrophysiological recordings, oocytes were placed on a nylon-grid in a bath of 
Xenopus Ringer solution (XR, containing 90 mM NaCl, 5 mM HEPES NaOH (pH 7.4), 1 
mM MgCl2, 1 mM KCl and 1 mM CaCl2). The oocytes were constantly washed by a flow 
of 6 mL/min XR which could be switched to XR containing GABA and/or drugs. Drugs 
were diluted into XR from DMSO solutions resulting in a final concentration of 0.1 % 
DMSO perfusing the oocytes. Drugs were preapplied for 30 sec before the addition of 
GABA, which was coapplied with the drugs until a peak response was observed. Between 
the two applications, oocytes were washed in XR for up to 15 min to ensure full recovery 
from desensitization. For current measurements the oocytes were impaled with two 
microelectrodes (2–3 mΩ) which were filled with 2 mM KCl. All recordings were 
performed at rt at a holding potential of –60 mV using a Warner OC-725C two-electrode 
voltage clamp (Warner Instruments, Hamden, CT). Data were digitized, recorded and 
measured using a Digidata 1322A data acquisition system (Axon Instruments, Union City, 
CA). Results of concentration response experiments were fitted using GraphPad Prism 3.00 
(GraphPad Software, San Diego, CA). The equation used for fitting the concentration 
response curves was Y=Bottom + (Top-Bottom)/(1+10^((LogEC50-X)*HillSlope)); X 
represents the logarithm of concentration, Y represents the response; Y starts at Bottom 
and goes to Top with a sigmoid shape.  
14. Behavioral experiments (with Savic et al.)82 
Experiments were carried out on male Wistar rats (Military Farm, Belgrade, Serbia), 
weighing 220-250 g. All procedures in the study conformed to EEC Directive 86/609 and 
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were approved by the Ethical Committee on Animal Experimentation of the Medical 
Faculty in Belgrade. The rats were housed in transparent plastic cages, six animals per 
cage, and had free access to pelleted food and tap water. The temperature of the animal 
room was 22±1ºC, the relative humidity 40-70%, the illumination 120 lux, and the 12/12 
h light/dark period (light on at 6:00 h). All handling and testing took place during the light 
phase of the diurnal cycle. Throughout the study the animals were used only once, with the 
exception of the grip strength measurement, which was done immediately after the tracking 
of behavior on the elevated plus maze. Spontaneous locomotor activity and elevated plus 
maze behavior were analyzed by the ANY-maze Video Tracking System software 
(Stoelting Co., Wood Dale, IL, USA). All drugs were dissolved/suspended with the aid of 
sonication in a solvent containing 85% distilled water, 14% propylene glycol, and 1% 
Tween 80, and were administered intraperitoneally in a volume of 1 mL/kg, 15 min before 
behavioral testing (for active and passive avoidance test, before the acquisition session). 
Time of administration, as well as, the doses of DMCM in various tests were chosen based 
on our previous studies (Savić et al., 2005a; 2005b; 2006). For interaction studies in the 
locomotor activity assay, the first treatment indicated in combination was administered into 
the lower left quadrant of the peritoneum 20 minutes before testing, and the second 
treatment 5 minutes later into the lower right quadrant of the peritoneum. 
Passive Avoidance (PA) Paradigm 
The experiments were performed in an adapted Automatic reflex conditioner (Ugo Basile, 
Milan, Italy, Model 7051), as described earlier.101 In short, the apparatus consisted of a 
shuttle-box, equipped with a grid floor and divided with a sliding door into a lit and a dark 
compartment, and a programming unit. The animals were submitted to two, 24 hour – 
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separated sessions. The acquisition session started by placing individual subjects in the 
illuminated compartment. After 30 seconds, the entrance to the dark compartment was 
opened, and as soon as the rat had entered it with all four paws, the footshock (2 s, 0.3 mA) 
was delivered. Immediately afterwards, the rat was returned to its home cage. The same 
procedure was repeated 24 hours later (retention session), without footshock. A cut-off 
time of 180 seconds was used on the training day, whereas, on the retention trial, a ceiling 
of 300 seconds was imposed. 
15. Measurement of Locomotor Activity (with Savic et al.) 
Activity of single rats in a clear Plexiglas chamber (40 x 25 x 35 cm) under dim red light 
(20 lux) was recorded for a total of 30 minutes, without any habituation period, using ANY-
maze software (as described above). For purposes of improving data analysis, the central 
20% of the chamber (200 cm2) was virtually set as a central zone. The minimum percentage 
of animal that must have been in the zone for an entry to occur was set at 70%, and 50% 
of the animal must have remained in the zone for an exit not to occur. 
16. Behavior on the Elevated Plus Maze (EPM) (with Savic et al.) 
The apparatus consisted of two open (50 x 10 cm, with a ledge of 0.3 cm) and two enclosed 
arms (50 x 10 x 40 cm), connected by a junction area (10 x 10 cm). The illumination in the 
experimental room was 10 lux on the surface of the arms. At the beginning of the 
experiment, single rats were placed in the center of the maze, facing one of the enclosed 
arms, and their behavior was recorded for 5 min. An entry into an open or closed arm was 
scored when 90% of the animal crossed the virtual line separating the central square of the 
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maze from the arm, whereas an exit occurred when more than 90 % of the animal left the 
respective arm. After each trial, the maze was cleaned with dry and wet towels. 
17. Grip Strength Test (with Savic et al.) 
Muscle strength was assessed by the grip strength meter (Ugo Basile, Milan, Italy, model 
47105). When pulled by the tail, the rat grasps the trapeze connected to a force transducer, 
and the apparatus measures the peak force of experimenter’s pull (in g) necessary to 
overcome the strength of the animal’s forelimbs grip. Each animal was given three 
consecutive trials, and the median value was used for further statistics. 
18. Statistical analysis (with Dr. Miroslav Savic) 
All numerical data presented in the figures were given as the mean ± SEM, except for 
results from the PA test (median latency with 25th, 75th interquartile range; data were non-
parametric because the procedure involved a cut-off). For electrophysiological data 
Student´s t-test was used for statistical analysis. Data from PA test were assessed by a 
Kruskal-Wallis non-parametric ANOVA, with post-hoc comparison relative to solvent 
control by a Dunn's test (α=0.05). Data from the AA, EPM, grip strength and activity assay 
were assessed by a one-way ANOVA. If the ANOVA was significant, each treatment 
condition was compared with control by a Dunnett's test (α=0.05). Where appropriate, the 
assessment of the antagonist influence on the inverse agonist effect was conducted by a 
student’s t-test. Statistical analyses were performed with ANY-maze Video Tracking 
System software (Stoelting Co., Wood Dale, IL, USA) and SigmaStat 2.0 (SPSS, Inc., 
Chicago, IL, USA).  
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II. Appendix I: Proton and Carbon Spectrum of PB-I-052 
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III. Appendix II: Proton and Carbon Spectrum of PB-I-054 
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IV. Appendix III: Proton and Carbon Spectrum of PB-I-056 
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V. Appendix IV: Proton and Carbon Spectrum of PB-I-059 
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VI. Appendix V: Proton and Carbon Spectrum of PB-I-060 
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VII. Appendix VI: Proton and Carbon Spectrum of PB-I-061 
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VIII. Appendix VII: Proton and Carbon Spectrum of PB-I-063 
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IX. Appendix VIII: Proton and Carbon Spectrum of PB-I-076 
 
 
 
